Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Cell Biol
2000 Dec 01;2023:8643-54. doi: 10.1128/MCB.20.23.8643-8654.2000.
Show Gene links
Show Anatomy links
Proteasome-mediated degradation of the coactivator p300 impairs cardiac transcription.
Poizat C, Sartorelli V, Chung G, Kloner RA, Kedes L.
???displayArticle.abstract???
The transcription of tissue-specific genes is controlled by regulatory factors and cofactors and is suppressed in cardiac cells by the antineoplastic agent doxorubicin. Here we show that exposure of cultured cardiomyocytes to doxorubicin resulted in the rapid depletion of transcripts for MEF2C, dHAND, and NKX2.5, three pivotal regulators of cardiac gene expression. Delivery of exogenous p300, a coactivator of MEF2C and NKX2.5 in cardiomyocytes, restored cardiac transcription despite the presence of doxorubicin. Furthermore, p300 also restored the accumulation of transcripts for MEF2C itself. Importantly, cardiocytes exposed to doxorubicin displayed reduced levels of p300 proteins. This was not due to alterations in the level of p300 transcripts; rather, and surprisingly, doxorubicin promoted selective degradation of p300 mediated by the 26S-proteasome machinery. Doxorubicin had no effect on the general level of ubiquitinated proteins or on the levels of beta-catenin, a protein known to be degraded by proteasome-mediated degradation. These results provide evidence for a new mechanism of transcriptional repression caused by doxorubicin in which the selective degradation of p300 results in reduced p300-dependent transcription, including production of MEF2C mRNA.
Avantaggiati,
Recruitment of p300/CBP in p53-dependent signal pathways.
1997, Pubmed
Avantaggiati,
Recruitment of p300/CBP in p53-dependent signal pathways.
1997,
Pubmed Avantaggiati,
The SV40 large T antigen and adenovirus E1a oncoproteins interact with distinct isoforms of the transcriptional co-activator, p300.
1996,
Pubmed Bishopric,
Adrenergic regulation of the skeletal alpha-actin gene promoter during myocardial cell hypertrophy.
1991,
Pubmed Ciechanover,
The ubiquitin-proteasome proteolytic pathway.
1994,
Pubmed Durocher,
The atrial natriuretic factor promoter is a downstream target for Nkx-2.5 in the myocardium.
1996,
Pubmed
,
Xenbase Durocher,
The cardiac transcription factors Nkx2-5 and GATA-4 are mutual cofactors.
1997,
Pubmed
,
Xenbase Eckner,
Association of p300 and CBP with simian virus 40 large T antigen.
1996,
Pubmed Eckner,
Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor.
1994,
Pubmed Eckner,
Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation.
1996,
Pubmed Edmondson,
Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis.
1994,
Pubmed Egan,
Mapping of cellular protein-binding sites on the products of early-region 1A of human adenovirus type 5.
1988,
Pubmed Grossman,
p300/MDM2 complexes participate in MDM2-mediated p53 degradation.
1998,
Pubmed Gustafson,
Identification of multiple proteins that interact with functional regions of the human cardiac alpha-actin promoter.
1989,
Pubmed Hochstrasser,
Ubiquitin-dependent protein degradation.
1996,
Pubmed Hochstrasser,
Ubiquitin, proteasomes, and the regulation of intracellular protein degradation.
1995,
Pubmed Huang,
Intramolecular regulation of MyoD activation domain conformation and function.
1998,
Pubmed Ito,
Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro.
1990,
Pubmed Janknecht,
Transcription. A growing coactivator network.
1996,
Pubmed Jeyaseelan,
A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes.
1997,
Pubmed Kamei,
A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors.
1996,
Pubmed Kitabayashi,
Phosphorylation of the adenovirus E1A-associated 300 kDa protein in response to retinoic acid and E1A during the differentiation of F9 cells.
1995,
Pubmed Kurabayashi,
Antineoplastic agent doxorubicin inhibits myogenic differentiation of C2 myoblasts.
1993,
Pubmed Kurabayashi,
Doxorubicin-induced Id2A gene transcription is targeted at an activating transcription factor/cyclic AMP response element motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase A.
1995,
Pubmed Kurabayashi,
Doxorubicin represses the function of the myogenic helix-loop-helix transcription factor MyoD. Involvement of Id gene induction.
1994,
Pubmed Levine,
p53, the cellular gatekeeper for growth and division.
1997,
Pubmed Lin,
Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C.
1997,
Pubmed Lints,
Nkx-2.5: a novel murine homeobox gene expressed in early heart progenitor cells and their myogenic descendants.
1993,
Pubmed Lyons,
Myogenic and morphogenetic defects in the heart tubes of murine embryos lacking the homeo box gene Nkx2-5.
1995,
Pubmed Murakami,
Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination.
1992,
Pubmed Ogryzko,
The transcriptional coactivators p300 and CBP are histone acetyltransferases.
1996,
Pubmed Orford,
Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin.
1997,
Pubmed Petrij,
Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP.
1995,
Pubmed Puri,
Differential roles of p300 and PCAF acetyltransferases in muscle differentiation.
1997,
Pubmed Puri,
p300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene transcription.
1997,
Pubmed Sartorelli,
Acetylation of MyoD directed by PCAF is necessary for the execution of the muscle program.
1999,
Pubmed Sartorelli,
Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C.
1997,
Pubmed Sepulveda,
GATA-4 and Nkx-2.5 coactivate Nkx-2 DNA binding targets: role for regulating early cardiac gene expression.
1998,
Pubmed
,
Xenbase Sheaff,
Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination.
2000,
Pubmed Shiama,
The p300/CBP family: integrating signals with transcription factors and chromatin.
1997,
Pubmed Verma,
A proteasome howdunit: the case of the missing signal.
2000,
Pubmed Whyte,
Cellular targets for transformation by the adenovirus E1A proteins.
1989,
Pubmed Yao,
The nuclear hormone receptor coactivator SRC-1 is a specific target of p300.
1996,
Pubmed Yao,
Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300.
1998,
Pubmed Yuan,
Human p300 protein is a coactivator for the transcription factor MyoD.
1996,
Pubmed
